Flotek Industries, Inc. (FTK) Earnings Call Transcript & Summary
March 16, 2021
Earnings Call Speaker Segments
Danielle Allen
executiveThanks, and good afternoon to all of you. On the line with me today and taking part in this call are John Gibson, our Chairman, CEO and President; Michael Borton, our Chief Financial Officer; TengBeng Koid, President of Global Business; and Ryan Ezell, President of Chemistry Technologies. During today's call, we'll begin with prepared remarks about our business and how we did in the quarter and the full year 2020. After that, we'll take whatever questions you have. This morning, our openings announcement for the fourth quarter and full year 2020 was released, and you can find it on our website. A webcast is underway for today's call, and a replay will be posted on our website as well. Keep in mind that anything we say today about projections or what we expect for future events counts as forward-looking statements. Such forward-looking statements carry a number of risks and uncertainties, and many of them lie beyond our control. Actual results could differ materially from what we currently expect because of these risks and uncertainties. Listeners should review our earnings release and the risk factors covered in our earnings filings with the SEC; in addition, please see the reconciliation included in our earnings press release, since management might discuss non-GAAP metrics on this call. With that said, I'll hand things over to John.
John Gibson
executiveThanks, Danielle, and good afternoon, everyone. Before we get into the quarter and the year, I'd like to give a brief operational update after last month's severe weather storm. The overwhelming majority of our employees located in Texas, Oklahoma, and Louisiana were affected by the strong storm, many going without power and water for days, myself included. It was genuinely a miserable experience for all who were hit. Several of our facilities did take damage, and for close to a week we couldn't get into the headquarters because of damage to our fire suppression systems, which have since been fixed. On top of that, we've felt the effects of the widespread force majeure declarations throughout the <<inaudible>> chemical supply chain — the first time we've witnessed such broad impact of this kind. Consequently, prices are climbing and supplies of certain raw materials are limited; we're lucky to have dependable supplier relationships and a robust supply chain sourcing strategy, which will allow us to keep delivering uninterrupted service to our valued customers, and we hope supply will start returning to a normal state within the next few weeks. This is somewhat of a somber moment before we really get into our results — I want to update you on the Board. It is with deep sadness that I report that Kevin Brown, one of our Directors, who came onto our Board in June 2020 after the JP3 acquisition, passed away unexpectedly in January. Kevin contributed a great deal to our Board and to the Audit Committee, and I valued his counsel and his insights, and he is missed. We extend our deepest condolences to Kevin's family and friends, and we grieve his loss together. Harsha Agadi was appointed to the Audit Committee in Kevin's place, and beyond that, we just announced that our Director, Michelle Adams, has informed the Board that she won't stand for reelection because of existing time commitments outside her responsibilities on the Flotek Board. Let me say this — Michelle is a superstar, and she's been a steadfast advisor to the Board since 2017, including her role as Compensation Committee Chair. She gave us her latest counsel on matters involving cloud-based technologies and the JP3 acquisition, compensation strategies, and business development methodologies. We're fortunate that we can keep working with her on the sales side for the next few months, but her presence in the Board group will be missed. I truly believe her career is on a rocket ship, since she's incredibly talented, and I look forward to watching her keep achieving great things. Because of that, we've engaged <<inaudible>> struggles to begin a search process for new directors. We'll keep you apprised of our progress. In addition, we've set up a new Board committee, the Risk and Sustainability Committee. Last year, through our Board assessment process, we identified the need to strengthen our risk oversight in order to build a resilient and sustainable business. Although the Audit Committee usually handles financial risks, our perspective on the dangers confronting the company now and later is considerably wider, encompassing human capital, ESG, cybersecurity, <<inaudible>>; we're thrilled that our standing Director Mike Fucci will chair the risk and sustainability committee, and working alongside Mike will be genuinely exciting. Looking back at how 2020 turned out, the resilience shown by our employees, our operations and the sectors we serve truly inspires me. The obstacles are remarkable, yet we stay concentrated and seize opportunities amid the pandemic within a hugely unstable macroeconomic setting. For several reasons, it proved to be a year of transformation. First, I take pride in the leadership team we've assembled — an inventive, responsible and outcome-driven group who is building Flotek in a sustainable way for what lies ahead. Second, we stepped into the digital transformation arena by acquiring JP3, which broadened our revenue sources further and stands as a superb long-term growth prospect. Third, earlier in the year, we acted swiftly and flexibly to cut our structural costs and refine our processes so we could operate more efficiently and safeguard our liquidity. Fourth, we broadened our chemistry offerings to encompass planning, disinfecting and sanitizing product lines. Following our <<inaudible>> efforts in the communities where we operate. Via this business, we are drawing on our current supply chain, current staff, current facilities to produce margin-accretive revenue. Through each of these steps, we sharpened our attention on environmental, sustainability and governance initiatives and culture; and we gave priority to protecting the environment, health, safety and security of our operations via our target of 0 incidents — nobody should ever go home injured. Thanks to these initiatives, we've boosted our adjusted EBITDA by over $7 million year-over-year to a loss of $26 million even though revenue fell by over half. Now, from a macro standpoint, the energy sector endured an exceptionally tough year throughout the entire hydrocarbon stream amid the oil price crash, COVID-19 demand destruction and the resulting oversupply of hydrocarbons. Consequently, capital budgets for domestic producers dropped sharply by over 40% year-over-year, according to a report by <<inaudible>> our customers prioritize their focus to accelerate the debt. More recently, we observe additional domestic uncertainty tied to the administration fees on new drilling on federal land and water, together with the cancelation of Keystone XL Pipeline as part of new climate change initiatives; nevertheless, we are finding grounds for a more optimistic outlook for the second half of 2021. As COVID-19 stay-at-home restrictions eased more broadly, vaccination adoption rates increased and more businesses opened. Although overall, capital budgets are projected to remain flat versus 2020 for some operators, activity is increasing from the lows of Q3 2020. One of our main strategies involved dividing the market based on activity levels. Through 2021, we're aiming at E&Ps that run steady programs and concentrate on acreage yielding the best margins. Throughout 2020, a lot of these producers kept their tenders going. On top of that, crude prices keep improving compared with the prior quarter — the U.S. Energy Information Administration now expects 2021 to average $61 per barrel across the year. Although refinery utilization is still soft on the whole, the rates have climbed consistently as we move into 2021, and we expect further gains as communities reopen globally. We've also noticed widespread indications of gasoline demand bouncing back, per the EIA. During mid-January, gasoline demand posted its biggest 1-week jump since June 2020, landing just above 6% below the 5-year average. Turning to the Middle East, optimism there stems from strong oil prices, and we're seeing greater need for our specialty, stimulation chemicals plus chances to adopt our digital technology. Koid will touch on that shortly. Our energy chemistry business especially enjoyed a very robust year in the Middle East, expanding 31% over 2019, and we plan to keep building on that proof point. When it comes to the gas sale market, we think a lasting shift is taking place in how businesses and consumers think, which will drive ongoing need for professional chemistry products.
John Gibson
executiveWith social interactions, more travel, and business events starting to return worldwide, we think demand for cleaning and sanitizing supplies is going to stay elevated as companies reinforce their protocols to rebuild consumer trust while keeping up their guard against emerging new variants of the coronavirus; and lastly, given growing corporate commitments around ESG, we're in a strong position to work alongside businesses looking to enhance their ESG performance. We accomplish this through health investment, improving the safety, reliability and efficiency of their operations by boosting natural gas production throughout the energy transition, and rolling out digital real-time technologies that drive process and operational efficiencies, cut waste to reduce the process. On top of that, we provide greener chemistry alternatives to the toxic chemicals currently used in portions of the energy production life cycle; and our solutions assist in lowering environmental risk. As you can see, we're eager to raise the level of our ESG conversations, and we look forward to sharing more with you over the course of the year; now turning to the quarterly results, just briefly for the fourth quarter. As we mentioned when the last earnings call wrapped up in November, we anticipated Q4 earnings would decline since our chemistry technologies was hit by year-end capital budget exhaustion, the effects of the COVID-19 resurgence on businesses, E&P consolidation and weakness in international activities. And the overall sense that the Thanksgiving asset pullback would return in the new year proved to be the correct direction. If those forecasts materialized, we broadly delivered in line with what we expected, with quarterly revenue and adjusted EBITDA down slightly from Q3. I'm glad we saw sequential improvement in our data analytics segment during Q4 as we refined our commercial model and carried out our sales strategy. JP3 is monetizing new opportunities, and we remain enthusiastic about the growth they achieved. Potentially in international markets, we reached a significant milestone, landing one of our first international pilots with TengBeng Koid to highlight in his comments. Now moving on to liquidity and cost <<inaudible>>, we keep taking decisive actions aligned with our strategic pillars to best position Flotek for the future. During the quarter, we kept working with our suppliers to negotiate raw materials costs, renegotiate recent leases and bring down the price cost. Safeguarding our balance sheet stays among our top priorities, and we have extensive options we are evaluating and pursuing to bolster financial flexibility. For more details on the quarter, I'm going to hand it over to TengBeng Koid for further discussion of our data analytics segment; then to Ryan Ezell, who will update us on the Chemistry Technology segment; and finally, to Michael Borton, who will give a more in-depth discussion of our financial results. With that, I am pleased to turn it over TengBeng Kold.
Teng Beng Koid
executiveThanks, John. Over the last quarter, we kept our attention squarely on carrying out the plan for our data analytics business; we keep showing customers the value we deliver by genuinely reshaping how they operate using real-time data and analysis. Thanks to our assets, we're happy to report revenue grew 91.8% on a sequential basis, and that came from new sales across North America plus maintenance and support services; during Q4, we also moved forward with our plan to enter international markets. As we mentioned three months ago, we've brought on an executive located in the Middle East who heads up our business development abroad. The engagement and positive feedback we're getting across the Middle East, Africa and Asia give us encouragement. In particular, we're excited to share that our first international pilot has been won. We're a top oil and gas firm in the Middle East, and planning for deployment has started. At the same time, we're preparing our products and systems so they meet what international deployments demand and expect. We're hitting key milestones with real momentum. International fields do take longer to develop, but gaining a foothold in this market matters greatly to our growth plan. Reaching this important milestone makes us happy, and we feel good about what lies ahead over the mid to long term. This quarter, we improved our software by speeding up our artificial intelligence and machine learning abilities. One of the earliest applications we intend to roll out in Q2 involves machine learning algorithms that shorten how long it takes to cut batches, which in turn cuts down further on transmix. By the way, transmix refers to the incidental blending that happens between neighboring batches of differing fuels moving through one shared pipeline. Having to reprocess or downgrade products because of transmix is expensive. If customers adopt our technology, they might save millions thanks to that lower transmix. On top of that, during the fourth quarter, we spotted a chance to make our strengthening process more efficient, which boosts our operational efficiencies, lowers what customers pay and speeds up commissioning of our systems. Over the years, JP3 has assembled a strong library holding over 30,000 hydrocarbon samples, and those are vital for our real-time hydrocarbon analysis work. Because our samples are so costly, we don't have to gather many additional ones. So we've made our process leaner, meaning we sample when needed instead of sampling just to grow the library. That yields better profitability and faster commissioning. So we're advancing considerably toward sampleless — that is, no samples — or sample-less — that is, fewer samples. During the fourth quarter, we brought on several new customers in the U.S; and in Canada. Typically, a new customer buys one system to test the technology. Once it's proven in the <<inaudible>>, that usually leads to more systems down the road. During Q4, one of the biggest midstream businesses in the United States became a client of ours. We've bought 4 more systems since that point. I feel enthusiastic regarding what lies ahead, because we keep upgrading what we offer, get better at how efficiently we deliver those solutions, and look for fresh clients and markets. JP3 technology changes the game — it assists our customers in earning more money, and it boosts safety across their operations for all of them. We're headed the right way to expand this business. Having said that, I'll hand the call over to Ryan Ezell so he can talk about our Chemical Technology segment. Your turn, Ryan.
Ryan Ezell
executiveThanks, Koid. To walk through how Chemistry Technologies did, I'll start with the main points on Energy Chemistry Technologies, and after that I'll cover the highlights in our professional chemistries, which takes in the cleaning, disinfecting, and sanitizing lines we've just launched that carry EPA and FDA registration. For our Energy Chemistry business, 2020 was a year of transformation, since we managed to push operational costs downward, go back to the table on logistics and supplier agreements, and speed up efficiencies across our business processes. That has left us with a leaner operation, one able to serve what the oil and gas market needs both now and going forward. In Q4, we started bringing Flotek back into the market so that more people could see our stronger value proposition, which centers our work on being the chemistry partner of choice while also delivering efficiencies in operational cost and better well production. Our sales approach is being refined so it fits a variety of customers at home and abroad, spanning E&P operators along with oilfield service companies. Within the domestic market, the customer base we're going after is one with sustainable activity in operational programs, especially in unconditional sale markets, and we're doing that through strategic objectives tied to Flotek's demonstrated performance and the value proposition of cost-effective chemistry solutions capable of proving production at a lower cost for each barrel produced. Take a recent case: Flotek gave an independent operator a customized solution to lift traditional asset simulation results for wells being returned to service in Andrews County, Texas, drawing on its proprietary reservoir centric chemistry. In that remediation application, utilizing our customized chemistry alongside acid treatment versus the acid treatment by itself yielded a 20% gain in production. What's more, that 20% production gain has held up over time when set against the control case of acids alone. Carrying out our value proposition turns out to be not just economically sound, given a positive return on investment, but also technically, because it shows customized chemistry can affect each and every variable in the capillary equation by raising the efficacy of the more traditional and repetitive applications now being implemented through wedge production cases to fight decline in this specific field. As a complement to our domestic strategy, our Energy Chemistry business keeps its attention on international growth opportunities, which are creating upside in the business, especially in the Middle East. Last quarter we noted that we had been named the Chemistry Partner of Choice in the Middle East, supplying a broad range of coiled tubing stimulation additives to a major NOC by working with the new market and international service companies. And although this is a multi-stage process, we're excited to watch the Middle East growth develop out of this opportunity. As of today, more than 25% of our current chemistry sales come from our international business, and we keep seeing significant growth opportunities in that region. Finally, as John mentioned, we're concentrating on speeding up our ESG solutions to improve customer effectiveness and profitability. Since 2011, Flotek has relied on its Green Check Chemistry Scorecard to assess, monitor, and disclose our ESG profile along with the products affected. Our patented chemistries rest on extremely efficient plant-based solvents, providing safer, sustainable substitutes for toxic chemicals derived from products that contain benzene, toluene, ethylbenzene, and oxylane—generally known as BTEX compounds. Such compounds cause serious harm to humans, soil, and groundwater, while our greener chemistry options create a safer environment for our workers, clients, and the communities we serve. We perceive a significant market chance to supply cost-efficient, eco-friendly, safer chemistry options that will broaden our product lineup while assisting operators in boosting output at a reduced expense per barrel. Turning to our professional chemistry line, I'd like to pause and consider what we've observed and what has been achieved so quickly. During 2020's second quarter, we introduced Flotek's FDA-grade hand sanitizers for industrial and consumer uses, and that range has since grown to over 10 distinct products within the janitorial and sanitizing space, thereby expanding our company revenue sources into a revitalized market with strong growth prospects. By using our chemical manufacturing strengths and ISO-certified plants, we brought our top-tier R&D capabilities to bear in delivering a growing array of premium FDA and EPA-registered items that naturally extend our chemistry technology portfolio. Today, I'm happy to share 3 key milestones for our chemistry—professional chemistry product lines. The first is a freshly signed strategic deal with a leading worldwide producer of specialty and intermediate chemicals. Following a thorough review and audit, Flotek received approval to manufacture and package EPA and COVID <<inaudible>> registered disinfectants and wipes as part of a chosen set of sub-registered firms. This arrangement also lets Flotek expand upon EPA-approved formulations within its innovation pipeline. Second, we've put money into developing our route to market to create a lasting, sustainable business approach by working with strategic adviser Matt Laszlo, a former Clorox executive. Matt carries over 25 years of expertise and has held senior business, sales, and marketing positions spanning consumer, commercial, retail, e-commerce, and industrial markets prior to joining us. His perspectives are assisting us in speeding up our loans and capitalizing on our strengths as we develop our business over the long haul. Last, in the fourth quarter, we're happy to announce the debut of our new professional chemistry brand Flotek Protocol, featuring a strong lineup of surface cleaners, wipes, disinfectants, green degreasers, and sanitizers made and produced in the U.S.A., with a focus on applying our proprietary green chemistry to the JanSan World; we welcome you to check out our website and discover our new product offerings. To wrap up, it's encouraging to see that the changes we've made in our Chemistry Technologies business are gaining traction, and we're making the operation more efficient as we respond to what our customers now require. At this point, I'll hand things over to Mike Borton, who will go through our financial results.
Mike Borton
executiveThanks, Ryan. As John said earlier, Q4 came in broadly as we had anticipated, even with the tough market conditions during the third quarter. During Q4, we dealt with global demand difficulties and industry headwinds that touched both of our segments. Even so, our loss is <<inaudible>> versus a year ago, since we are running the business with greater efficiency and pursuing fresh approaches to generate, broaden, and develop profitable revenue sources. To begin, I want to discuss the impairment recorded in Q4 within the Chemistry Technology segment. We posted a $9.4 million loss tied to the amended <<inaudible>> agreement, reflecting changes in how much the company expects to use <<inaudible>>. That <<inaudible>> purchase stems from a take-or-pay contract connected to the 2019 <<inaudible>> chemical company that was reported into ADM. The earnings per share effect tied to those <<inaudible>> entries comes to a loss of $0.16 per diluted share, within a total loss of $0.30 per diluted share. Let's now walk through the income statement more closely. Consolidated revenue for Q4 totaled $12.1 million, a 5% drop from $12.7 million in Q3 and under the $19.5 million recorded in the same period a year earlier. The Q4 decrease mainly reflects macro environment volatility affecting U.S. onshore loan and completion activity, which political and economic developments abroad influence, along with product mix within the Chemical Technologies segment. Looking segment by segment, revenue supply chain in the Chemistry Technology segment fell 10%, landing at $10.8 million, compared with $19.5 million of revenue during last year's fourth quarter. That decrease was mostly attributable to normal Q4 seasonality combined with lower year-over-year activity levels stemming from the continuing marketplace. Sales in the data analytics segment rose 91.8% quarter over quarter, fueled by growth in new <<inaudible>> sales across North America. Consolidated operating expenses came to $24.3 million in Q4 of 2020, down 17.4% from the prior quarter and 42.6% lower than last year's $42.4 million figure for Q4. Corporate G&A fell $5.2 million to $3.7 million, versus $9 million in last year's fourth quarter, because of reduced overall completion, compensation spending, and lower discretionary spending, including professional fees, partly offset by one-time severance charges and discretionary balances. Corporate expenses rose on a sequential basis owing to an accrual for the specialty growing statements, which reduced adjusted EPS by under $0.01 per diluted share. Our depreciation and amortization expenses dropped $1.8 million to roughly $235,000 in Q4, compared with $2 million a year ago. Research and development costs reached $1.5 million in Q4, essentially flat versus Q3 and lower than last year's $2.2 million; we recorded a loss from continuing operations of $17.7 million, or $0.30 loss per diluted share, in Q4 of 2020. A steeper <<inaudible>> loss came in at $36.9 million, equivalent to $0.64 per diluted share, for last year. Adjusted EBITDA in the fourth quarter showed a loss of $6.8 million, and that figure is not merely an improvement over the $8.5 million loss posted in last year's fourth quarter. Lower operating expenses, resulting from adjustments to headcount, are the main driver behind this adjusted EBITDA improvement. Looking ahead to 2021, we aim to get the most out of cost efficiencies, expand our top line, and obtain the working capital required to carry out our growth strategy. In pursuit of that, we plan to act on our chances to grow our energy focused products and services on an international scale. We also intend to increase domestic market share of <<inaudible>> as the energy market rebounds during the latter half of 2021, and to broaden our green chemistry and ESG related product offerings. Let's now turn to how the balance sheet performed. Our cash position continues to be healthy. Preserving our liquidity is where our focus lies. When the fourth quarter ended, cash equivalents stood at $38.7 million, compared with $49.2 million during the third quarter. Four key factors were behind the decline, each affecting our cash position. These were operating losses, a $2.5 million earn-out provision tied to the JP3 acquisition, capital improvements for our package and bottling equipment within our Chemistries Technology segment, and <<inaudible>> as well. Under the Paycheck Protection Program connected to the CARES Act, the company carried a combined $5.7 million in outstanding loans. During the previous quarter, we highlighted that better managing our inventory position ranked among our priorities, and we cut our fees by 35%; a modest additional reduction has been made this quarter, and we still anticipate that reducing SKUs will deliver annual savings somewhere in the $1.1 million to $1.3 million range in ambulatory <<inaudible>>. With that, I'll hand the call back to John so he can give his closing remarks.
John Gibson
executiveThanks, Mike. About a year ago from now, I told all of you that I'd accept a bonus for 2020 only on the condition that the company hit breakeven or did better; that didn't happen. Of course, back when I made that pledge, there was no way I could have imagined what was coming, yet our ambitions and our goal stayed the same. So, staying true to my word, I turned the bonus down. Let me be clear: although 2020 didn't deliver the result we were aiming for, I feel really good about what we accomplished during 2020 and about the improvement in adjusted EBITDA from one year to the next even with revenue coming in lower; and I'm extremely thankful for the backing of our Board, our management team, and our employees — especially the Board, who acknowledged my leadership along with what we achieved amid the hardest circumstances I've faced in my whole career. On January 6, I marked 1 year with Flotek. And even though optimism is part of who I am, I'll be honest — there were moments when that optimism faded; it never lasted, though, because the instant one challenge appeared, some opportunity showed up too. I can't express how thankful I am to our customers, who put their trust in us to stand behind them throughout this unprecedented year, and also how deeply I appreciate the backing from our shareholders, a lot of whom have opened doors and resources for us as our business transformation got underway. And it's our employees who motivate me every day through their bravery, creativity, and expertise. Above all, I'll forever treasure the calls and e-mails of encouragement that arrived exactly when I needed them. Thanks, everyone. With that, let's open the line for questions.
Daniel Burke
analystAlright, let's see here. John, perhaps we kick things off with something fairly broad. I believe all of you touched on this somewhat. Still, what's your outlook on the rate at which cash is being burned during 2021, and what steps might lessen that? And possibly, can you get to that point where you cross over into generating positive cash as the year goes on?
John Gibson
executiveThat's an excellent question, and for everyone here at the company, liquidity is likely top of mind. So I've been speaking with Mike, and one item to examine from the prior year is which expenses were nonrecurring? If you add those up, they'll fall within a $28 million to $30 million range—things we don't expect to happen again this year. Subtract that from the roughly $60 million we used, and it means we expect to spend around $30 million this year too, assuming a year similar to the last one. As a result, we have enough cash to get through 2021; and since we view this as a year of recovery, it's somewhat difficult to predict precisely when the market will improve. Even so, we believe there won't be any unusual cash expenses in 2021. Additionally, we have multiple efforts in progress to actually cut that $30 million in extra spending this year by being somewhat stricter regarding certain outlays on supply chain, and so on. Thus, I expect us to finish the year in solid shape. We possess more than enough cash to cover all our obligations this year.
Daniel Burke
analystAll right. And perhaps, just to remain on the subject of cash, so to speak. Regarding terpene, all of you recorded a charge during Q4. My understanding is that your obligation to buy terpene rises in '21 compared with '20. Could you give us confidence that, I suppose, following this Q4 charge, you've set aside an adequate reserve for the volume of terpene sales likely to be realized in 2021.
John Gibson
executiveYes, I definitely think our reserve is adequate. And we're developing approaches to lower the purchases of terpene that will be needed down the road. And I'll need to share more on that with you as things progress; but we — certain factors really have an effect on that. Alternatively, we've conducted a substantial amount of research, and we've made our products more competitive on price and better in performance even while reducing how much terpene is needed to supply those products. So that lowers our cost of goods and lifts our margins. And simultaneously, we're observing excellent performance from these chemicals, in fact superior to the pricier <<inaudible>> terpene of earlier times; that lessens the demand for terpene; so you can take it that cutting the quantity of terpene we buy is essential for us, so that we aren't buying beyond our supply, and we're pursuing a fix for that issue.
Daniel Burke
analystAll right, I have a few additional questions to ask. Perhaps one regarding JP3. I realize that JP3 has been going through a transition as you refashion the sales model. However, during '18/'19, that business was operating at a quarterly revenue run rate of $3 million to $4 million. So, as you look toward possibly the second half of '21, could you share any thoughts on whether getting back to that revenue level is viable?
John Gibson
executiveI'm quite enthusiastic about it. Koid probably has the best response for that. Koid, if you could jump in.
Teng Beng Koid
executiveI appreciate that, John, and thank you as well, Daniel. Our efforts span both overseas and here at home; when it comes to markets abroad, I believe significant opportunities exist that we're actively pursuing, and those will enable us to propel the company forward and expand it considerably down the road. On the home front too, things are accelerating. Within the country, we're likewise observing an upturn and a turning point. As a result, we're having many more conversations with customers and seeing that shift; in fact, going to a client's office happened for me last week for the first time in 12 months — previously it was lunches, dinners, <<inaudible>> and the like. And a year ago — only seven days back, we found ourselves at the site of one of our biggest clients; so that inflection is clearly gaining momentum as we progress through this year.
John Gibson
executiveThere's also something else that stood out. We met for breakfast at <<inaudible>> alongside one of the big employers. Here's what he told us, word for word: "In 13 months, this is only the second in-person meeting I've attended." That should give a sense of how tough it is for this company, and for the entire sector, to get their sales activity moving upward. The question becomes how fast they can get that going. Thanks to JP3, we're starting to see folks accepting meetings. Koid has been traveling. Koid — this may break some HR policy, I suppose — Koid has gotten 2 shots. I've gotten one shot, and we're pushing to get that shot so all of us can be out visiting customers. I'm looking forward to my second shot next week, which will let us get on the road. All of us are dedicated to going out and holding those individual, face-to-face meetings with customers the moment they unlock their doors and welcome us in.
Daniel Burke
analystI'm with you; that sounds — getting back to normal will be nice. All right. Perhaps one last thing. Just working through the K here. I simply spotted a handful of cases where material weaknesses were flagged. Could you perhaps explain what's happening there, and what you'll do about them?
John Gibson
executiveThanks for that, Daniel. Yes. I mean, material weaknesses do exist, and much of it relates to internal controls. And I took over those controls from a game here in 2020, and we've launched many initiatives to boost our capacity to put in place controls that actually matter. We did swap out directors. We replaced the Audit Committee chair. This year, we plan to move the internal audit function in-house since we believe that will give us far more oversight over it as we move ahead. And every material weakness that's been noted is something we can fix right away and test, finishing within 2021. And so — and in certain cases, it's somewhat frustrating. Because taken together, we have controls that would really have taken and delivered the control that was needed, but no specific control was named as what was required. And so we need to work through and examine our controls and confirm we have specific main controls that satisfy the requirements that appear to be emerging today.
Charles Fratt
analystSo, this is actually about the professional chemistry segment. Considering the programs you've got going, what interests me the most is the Protekol product launch; and could you, like, put some numbers on when that's coming and how much revenue that new line could bring?
John Gibson
executiveI'll give it a shot. Ryan is sitting here with me; we've got a full-time consultant working with us, Matt Laszlo, who joined us from Clorox, and in his view we've truly excelled at generating revenue in the professional chemistry lines; but he's a consultant, and we do have the manufacturer. We secured registration with both the FDA and the EPA; our facility has been modified so we satisfy every requirement in preparation for inspection. We laid the groundwork to be genuinely strong in this business going forward. And the final item we held back, since we didn't want to begin selling before product was available, is building the sales force. So Ryan has been pursuing sales talent hard. It's proven a bit tougher than I'd expected, mainly because if you're employed at one of the giant <<inaudible>> chem companies this year, COVID-19 begins eating into your budget; so you're just sitting there waiting for your bonus before you take the chance and move to another company. That's why bringing people aboard has been somewhat delayed. Still, I believe we are — we've got several candidates. Ryan, go ahead and chime in.
Ryan Ezell
executiveNo, what I'm saying is, John, that's <<inaudible>>. In my view, this is an area of the company that has us genuinely enthusiastic, given what it offers as a revenue stream that adds to earnings. Our capabilities with the FDA and the EPA as regulatory agencies are solid. And as far as we're concerned, we keep witnessing how our product sales develop and how the channels we use diversify across most of the customers we serve — what initially looked like those triage-type <<inaudible>> have turned into buyers who come back, and they keep expanding and maturing along those lines. The potential for growth here has us truly thrilled. We also believe that launching the Protekol brand is beginning to create real confidence that we will remain a long-term participant in this market, and it's bringing considerable attention our way because of the growth angle, which we're very enthusiastic about.
John Gibson
executiveI'm not going to spend much time on this topic, but something I find really interesting about it is how many unreliable, <<inaudible>> nights ended up involved in this. To actually secure a contract, one thing we need is hard evidence of inventory. That means heading into the warehouse with a camera to demonstrate we truly have goods available to ship. They insist on confirmation because they've placed orders before and never gotten them. I think that's an area where you're going to see lawsuits all through this year and the next, tied to businesses that pledged things they couldn't fulfill — and that's a trap we've steered clear of.
Charles Fratt
analystExcellent. Then, Mike, you said there were 2 PPP loans still open — 1 with the business you bought, plus another at Corporate. Could you walk us through how you're handling the forgiveness application under the CARES program? Have you gone through it yet? If you've already filed for forgiveness, when do you expect to hear back?
Mike Borton
executiveAt this point, it's simply a matter of completing the paperwork. We'll likely send everything over to the SBA at some point during the coming month.
Eric Swergold
analystThere are a couple of things I want to ask. Mike, the first one's for you. As of year-end, what do the total NOLs come to — could you walk me through that again? Then for TengBeng: clearly you weren't just sitting around doing nothing, even if traveling wasn't possible. Now, compared with how things stood 9 months ago, what does your prospect look like today for the data business? Since you've clearly had plenty of time to look into who the potential customers are for that line of work you're doing now, can you speak to that a bit?
Mike Borton
executiveRoughly $95 million is what we refer to as our NOLs. Under the older loss carryforward approach fall about half of them, meaning some had to be carried forward by us, at 80% definitely, and roughly half is what that represents, while the remaining half defer and expire near 2032, 2035. So of that $95 million, it's about 50 to 50. Between 2032 and 2035 some will expire, while others carry on forever. Thanks.
Teng Beng Koid
executiveWhen it comes to our home markets — Canada, and I suppose the U.S. and Canada together — repeat buyers are returning, both during the fourth quarter and in the current one. So that piece is progressing well. On the international side, we've put substantial business development work into Asia, Southeast Asia, India, and throughout the Middle East too. A good number of those conversations have turned into proposals, so we're feeling optimistic about the international front, though it will still require some time, given we can't travel or hold in-person meetings, but the responses coming in from everywhere are suddenly quite positive.
John Bair
analystI've got a few things to ask. As you work toward transitioning, or start moving into, creating greener chemistry options for well stimulation and similar applications, could you give us a sense of the timeline involved — from initially courting a potential customer to that customer actually trying and testing the product? My assumption is they'd want to run some trials before you'd realistically land a consistent, meaningful flow of orders from that.
John Gibson
executiveJohn, that's an excellent question. As it happens, this company's history shows it was established around green chemistry. And that was likely at a time when most people offered little more than lip service to it and didn't treat it seriously. Yet with that same major independent this morning, we discussed ESG, where the E carries enormous weight, and their definition of it would be clean air along with clean water. So that's genuinely something important to keep in mind. Increasingly in this industry, discussion of climate change will fade, but attention will land on the environmental side — clean air, clean water — which translates to less flaring and removing toxic chemicals from every area, be it production chemicals, completion chemicals, and so on. So where do we stand? Well, those product lines already exist on our side. In fact, we closed a sale of clean, green chemistry in California here. It wasn't especially large, but it signals that we're capable of supplying that chemistry today. One challenge I see is that we truly need to push harder on marketing it and on discussing it with customers. Even this morning, talking with the customer we met, one point they shared that I find remarkable is that they've set up a clean air, clean water fund — so when the expense of adopting that technology runs higher than using the less desirable, more toxic chemicals — and I should give an example, such as xylene, which is considerably more carcinogenic — then we're able to step in with terpene based solutions and — or other other solutions to take its place, and they will in fact subsidize it so their own operations staff start putting greener chemistry to use; so I'm enthusiastic that our customers are treating this seriously. And it's not lip service anymore. This is an industry that I believe is pushing ahead aggressively — not in marketing, but in genuine commitment to becoming better environmental stewards, and that's taking place; so I think that will bode well for us. We need to market, and the chemistry we possess is available. It simply comes down to us talking with customers, blending and sending.
John Bair
analystDo those programs include both the green chemistry part and the monitoring and sensors you provide? I've been to a few of your presentations recently, so I'm attempting to catch up on what you all are doing. But is it — is it sort of a bundled offering like that? Or is it only the chemical products going downhole into the wells?
John Gibson
executiveYes. So for this, we aren't as well bundled and productized as we really probably ought to be. There's clearly more work ahead of us on this front. I genuinely think it will pay off substantially, both for the business and for the people we serve, so that question is a great one. It's also driving a large share of the conversations we're having. These days, when we meet with customers, one of the earliest things they raise — on a video call or face to face — is how they should go about meeting their organization's ESG obligations. Take another illustration: it now factors into pay. So it has stopped being some abstract concept. Instead, it is built right into how they're compensated. So I'd say that helping them do better on their bonus is a really strong selling point for Flotek.
John Bair
analystLet's move to a different topic for a moment. From what you've told us, those 2 plants of yours operate a single 8-hour shift, which means there's room to grow should demand call for it. So with the FDA certifications and EPA certifications and all of that now in hand, I'm curious whether you're noticing any real increase in inquiries, or on the product sales side, that would push you toward considering the great prospect of bringing on an additional shift?
John Gibson
executiveHow I wish that's what we were discussing right now — a second shift. The funny thing is, orders tend to arrive in waves and bursts, so at certain points we're already putting in some overtime just to ship everything out, while at other points we genuinely have idle time. Do we require a second shift at this moment? No, we don't. And my feeling is that the instant I brought on a second shift, I'd want to come straight to you folks and report it, and I'd say that we're truly starting to gain traction in the market.
John Gibson
executiveOkay, as usual, thank you for being on this call, and we truly value the backing from each of our shareholders. We've also had customers who stuck with us in a really dedicated way throughout this period. And I simply want to ensure it's clear how much you matter to us; and above all, our employees have delivered some outstanding royalty results. So we've found a way to make it through a difficult twelve months. And then, believing we were coming out of it thanks to the vaccine, we still had to get past some harsh weather conditions. And so I'm grateful for the resolve, the dedication, and the faithfulness that every one of our employees has demonstrated toward this company; and working here has just been tremendous; and I'm eager to speak with you all once Q1 wraps up. Take care.
Operator
operatorThat brings us to the end of this call. We appreciate everyone joining us for today's presentation. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Flotek Industries, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Flotek Industries, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Flotek Industries, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.